Trending...
- NKF Awards Indiana Registered Dietitian with Kopple Award - 144
- Boston: Mayor Michelle Wu Announces City's Black History Month Programming
- Boston: February is Black History Month
CAMBRIDGE, Mass. ~ Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will be hosting a virtual R&D Day event on Wednesday, December 13th at 8:30 am ET. The event will be webcasted on the Investors section of the Company's website, www.alnylam.com, and a replay will be available within 48 hours after the event.
Alnylam Pharmaceuticals is a biotechnology company that has been translating RNA interference (RNAi) into innovative medicines since its founding in 2002. The company has developed five commercial RNAi therapeutic products: ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran). Alnylam also has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.
More on Boston Chron
The company is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance. Alnylam is headquartered in Cambridge, MA and for more information about their people, science and pipeline can be found at www.alnylam.com or by engaging with them on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.
Christine Regan Lindenboom serves as contact for investors and media inquiries while Josh Brodsky serves as contact for investor inquiries at +1-617-682-4340 and +1-617-551-8276 respectively.
Alnylam Pharmaceuticals is a biotechnology company that has been translating RNA interference (RNAi) into innovative medicines since its founding in 2002. The company has developed five commercial RNAi therapeutic products: ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran). Alnylam also has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.
More on Boston Chron
- Retired Leadership Facilitator Shares Decades of Wisdom in New Book
- Boston: Mayor Michelle Wu Shares City's Preparations and Reminders to Residents Ahead of Snowfall
- I belong (t)here, an exhibition that explores the fluidity of identity and the search for belonging in a world that is constantly shifting
- NKF Awards Indiana Registered Dietitian with Kopple Award
- Js Art Gallery: A New International Art Space Promoting Unity Through Art
The company is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance. Alnylam is headquartered in Cambridge, MA and for more information about their people, science and pipeline can be found at www.alnylam.com or by engaging with them on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.
Christine Regan Lindenboom serves as contact for investors and media inquiries while Josh Brodsky serves as contact for investor inquiries at +1-617-682-4340 and +1-617-551-8276 respectively.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Earn passive income through DAY Miner cloud mining in 2025
- Vane Airport Media Inc, The Best Travel Idea of 2025
- HVAC Systems: The Unsung Heroes in the Fight Against Flu Season
- Capstone Partners & IMAP Release 2024-2025 Trends in Global M&A Research Survey:
- Gold Coast Health Plan Distributes $225,000 for Fire Relief and Preparedness Efforts
- The Dallas Group of America, Inc. Celebrates the 50th Anniversary of Landmark Facility
- Boston: Mayor Michelle Wu Announces Annual Tax Prep Services Available for Residents
- Dog Licensing Reminder (and Boston's Most Popular Dog Names!)
- Kelvin Emtech and Colm Engineering Unveil Strategic Joint Venture, to Boost Data Center and Building M&E Capabilities
- The Twelfth Tony Del Plato Mystery Debuts
- TiE Boston and Venture Development Center (VDC) at UMass Boston to Collaborate on the AI VC Forum
- Eagle Coins Gold & Silver Buying: Trusted Gold and Coin Buyers Near You
- From Corporate Identity Theft to Business Success
- Leading change makers and industry experts join The Possible Zone Board of Directors
- Citizens for West Virginia Election Integrity Calls for Urgent Reforms to Safeguard State Elections
- The Arc of South Shore Announces Elizabeth Sandblom as CEO
- Patton Launches SFP-based RS-232/422/485 Serial Device Server
- Local Tech Entrepreneur Partners with WonderSouq To Offer Downtown Medford Businesses a Virtual City Experience
- Boston Bridal Atelier Enhances Luxury Experience with New Bridal Shop Location
- New Website for Solo Agers Over 50